Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 26;18(12):2873–2884. doi: 10.1111/ajt.14874

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Promotion of graft survival and upregulation of T regulatory cells in vascularized high‐risk eyes after pretreatment with corneal crosslinking (CXL). A. The 9‐minutes CXL treatment before corneal transplant significantly promoted corneal allograft survival in pretreated high‐risk eyes 8 weeks after corneal transplant (control: 25.0% survived, 9‐minutes CXL: 66.7% survived; n = 12; *P < .05). B,C. There were significantly more CD4⁺ CD25⁺FoxP3⁺ cells in draining lymph nodes in the 9‐minutes CXL‐treated group than in the control group at 8 weeks post corneal transplant (n = 12; **P < .01). FACS analysis showed no statistical difference for CD3⁺, CD4⁺, CD8⁺, CD11b⁺, CD11c⁺, or CD45⁺ cells